Development of Novel Antiatherogenic Biaryls: Design, Synthesis, and Reactivity. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Journal of Medicinal Chemistry Année : 2008

Development of Novel Antiatherogenic Biaryls: Design, Synthesis, and Reactivity.

Résumé

On the basis of the 5,5'-bisvanillin scaffold, a series of compounds has been synthesized presenting symmetric or dissymmetric frames on each phenolic moiety. These frames are alpha,beta-unsaturated (fluoro)phosphonate and/or alpha,beta-unsaturated hydrazone(s) formed by coupling aldehydic with isoniazid or hydralazine. All compounds were tested for their ability to inhibit cell-mediated low-density lipoprotein oxidation. Oxidized low-density lipoprotein induced cytotoxicity was also evaluated along with the carbonyl scavenger properties of selected compounds. The most efficient agents were found to be those possessing at least one hydralazinone frame, with the most potent being the symmetrical compound: 4,4'-dihydroxy-3,3'-dimethoxy-5,5'-biphenyl-1,1'-(diphthalazin-1-yl)methylhydrazone hydrochloride.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-00279925 , version 1 (15-05-2008)

Identifiants

Citer

Mélanie Delomenède, Florence Bedos-Belval, Hubert Duran, Cécile Vindis, Michel Baltas, et al.. Development of Novel Antiatherogenic Biaryls: Design, Synthesis, and Reactivity.. Journal of Medicinal Chemistry, 2008, 51 (11), pp.3171-3181. ⟨10.1021/jm7014793⟩. ⟨inserm-00279925⟩
178 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More